Back to Search
Start Over
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders
- Source :
- Neurology® Neuroimmunology & Neuroinflammation, article-version (Version of Record) 3
- Publication Year :
- 2020
- Publisher :
- Lippincott Williams & Wilkins, 2020.
-
Abstract
- Objective To report pregnancy outcomes and disease activity (DA) in women with MS, neuromyelitis optica spectrum disorders (NMOSDs), and other neuroimmunologic diseases (ONID) after treatment with rituximab (RTX)/ocrelizumab (OCR) 12 months before or during pregnancy. Methods Data were collected in the German MS and pregnancy registry and centers from the Neuromyelitis Optica Study Group. Sixty-eight known outcomes of 88 pregnancies from 81 women (64 MS, 10 NMOSD, and 7 ONID) were included and stratified in 3 exposure groups: >6M-group = RTX/OCR >6 but ≤12 months before the last menstrual period (LMP) (n = 8)
Details
- Language :
- English
- ISSN :
- 23327812
- Volume :
- 8
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Neurology® Neuroimmunology & Neuroinflammation
- Accession number :
- edsair.pmid..........a79f08e4ac662ecfc73ea1ba1d4a4680